Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore
Sattva Sukun Lifecare Ltd · Others (Uncategorized) · 12 Oct 2026, 8:46 pm
Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore Tavexia Lifecare Limited has approved the acquisition of a 60% controlling equity stake in Meyonex Pharmaceuticals Limited via a cash subscription of 2,09,97,180 fresh equity shares priced at ₹32 per share, totaling ₹67.19 Crore. The deal grants Tavexia immediate manufacturing and commercial infrastructure in MIDC Tarapur, Maharashtra. Alongside strategic expansion into APIs, finished formulations, CDMO/CRAMS, and nutraceuticals via an altered Object Clause, the company plans to fund the transaction through equity or convertible instruments.
Original exchange filing (PDF)
More announcements from Sattva Sukun Lifecare Ltd
- Financial Result · 05 Nov 2026
- Announcement · 05 Nov 2026
- Board has Approved in Change in RTA · 05 Nov 2026
- Result · 05 Nov 2026
- Outcome of Board Meeting · 05 Nov 2026
- Tavexia Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting · 04 Nov 2026
- Announcement · 13 Oct 2026
- Disclosure under regulation 30 · 08 Oct 2026
